Abstract
Rationale:
Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC.
Patient concerns:
We reported a 49-year-old woman presenting with a giant breast tumor.
Diagnoses:
Stage IV TNBC with chest wall metastasis.
Interventions:
The patient underwent long-term use of bevacizumab combined with chemotherapy.
Outcomes:
The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed.
Lessons:
Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / administration & dosage*
-
Carcinoma, Ductal / drug therapy*
-
Carcinoma, Ductal / pathology
-
Carcinoma, Ductal / secondary*
-
Cisplatin / administration & dosage
-
Female
-
Humans
-
Middle Aged
-
Thoracic Neoplasms / drug therapy*
-
Thoracic Neoplasms / pathology
-
Thoracic Neoplasms / secondary*
-
Thoracic Wall / drug effects
-
Thoracic Wall / pathology
-
Treatment Outcome
-
Triple Negative Breast Neoplasms / drug therapy*
-
Triple Negative Breast Neoplasms / pathology
-
Vascular Endothelial Growth Factor A / drug effects
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
Cisplatin